JPRN-UMIN000051378
Not yet recruiting
未知
A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancer - A retrospective observational study of trifluridine tipiracil plus minus bevacizumab in pretreated mCRC patients with MSI-H MMR-D metastatic colorectal cancer
The 22nd Century Cutting-Edge Medical Informaion Technology Organization0 sites15 target enrollmentJune 19, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The 22nd Century Cutting-Edge Medical Informaion Technology Organization
- Enrollment
- 15
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Presence of multiple life threatening cancers 2\.Inappropriate cases by physicians judgement
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G)JPRN-UMIN000044136West Japan Oncology Group140
Recruiting
Phase 2
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5- fluorouracile ± nivolumab in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer2024-512999-35-00Unicancer118
Active, not recruiting
Not Applicable
Real-world Effectiveness and Safety of Trifluridine/Tipiracil plus bevacizumab in Metastatic Colorectal Cancer: A retrospective observational study using an administrative databaseColorectal cancerJPRN-jRCT1031220116Taiho Pharmaceutical Co., Ltd. Medical Affairs Division11,962
Not yet recruiting
Not Applicable
Pooled safety and efficacy analysis of trifluridine/tipiracil plus bevacizumab in five clinical trials using individual data from patients with metastatic colorectal cancermetastatic colorectal cancerJPRN-UMIN000041621The 22nd Century Cutting-Edge Medical Informaion Technology Organization239
Completed
Phase 2
A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapyER-positive breast cancerMetastatic breast cancerHer2 negative10006291NL-OMON52884BOOG Study Center50